Surgery plus drug: a new combo for obesity?

NCT ID NCT06734273

Recruiting now Disease control Sponsor: Nicholas Skertich Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study looks at whether taking tirzepatide (Mounjaro) after sleeve gastrectomy surgery helps people lose more weight and improve conditions like diabetes and high blood pressure. About 42 adults with obesity will be split into two groups: one gets surgery alone, the other gets surgery plus the drug. The goal is to see if the combination is more effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (Mounjaro)
What this could lead to: If it works, this could point toward a more effective weight-loss strategy combining surgery and medication for people with obesity.
What could go wrong: This is a very early, small trial with only 42 people, so results may not apply widely. Adding tirzepatide after surgery could also increase side effects or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND OBESITY-RELATED MEDICAL CONDITIONS

Contacts and locations

Locations

Rush University Medical Center
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.